The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

Also called NCT02982434

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02982434
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02982434. Randomized; double masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
Condition
Ischemic Heart Disease
Intervention (Drug)
Pharmaceutical composition containing botulinum toxin
Intervention (Drug)
0.9% normal saline
Intervention (Procedure)
Coronary artery bypass grafting
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation (class: research network)

Record details

Record id
cardio:ct-nct02982434
Content hash
cc10a7b0223f577c5fc2ebb394f4fefcbe7e64a7833422abbfea59f7a364fa83